Mechanisms of Protective Immunogenicity of Microbial Vaccines of Military Medical Significance

Michael S. Ascher, M.D.
Monique A. Berman, Ph.D.

Department of Medicine
University of California, Irvine

U.S. Army Medical Research and Development Command
Fort Detrick, Frederick, MD 21701-5012

Approved for public release, distribution unlimited

Initial clinical studies of Phase I Q fever vaccine (IND #610) and skin test were performed under this Contract. A total of 242 volunteers received skin tests and 22 received vaccine at two dose levels. Skin test reactions were classified according to the duration of persistence of erythema and skin test results were correlated with serologic and in vitro lymphocyte stimulation results. A role for lymphocyte testing in predicting skin test reactions was
defined. In response to vaccine, local reactions were minimal and without abscess or granuloma formation. Immunologic results show consistent antibody responses and variable lymphocyte transformation responses to Q fever antigens.

Dermal granulomatous skin reactions seen to Q fever vaccine antigens in immune guinea pigs have been analysed for their immunologic basis. New information has been obtained on the interrelations between antigens of C. burnetii and their relative contributions to granuloma formation. A purified fraction of C. burnetii obtained by extraction with chloroform and methanol (CMR) has been characterized as a skin and lymphocyte antigen in man and guinea pigs. CMR is devoid of granuloma reactivity but carries the determinant for delayed hypersensitivity and lymphocyte stimulation.

A solid phase (FIAX) immunofluorescent assay procedures was developed for serodiagnosis of Q fever and used in the evaluation of volunteers responses to Q fever vaccine and skin test as well as in an intensive national surveillance program.
Mechanisms of Protective Immunogenicity of Microbial Vaccines of Military Medical Significance

Annual and Final Summary Report

Michael S. Ascher, M.D.
Monique A. Berman, Ph.D.

15 May 1984

Supported by

U.S. ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMAND
Fort Detrick, Frederick, Maryland 21701-5012

Contract No. DAMD17-80-C-0154

University of California, Irvine
Irvine, California, 92717

Approved for public release, distribution unlimited

The findings in this report are not to be construed as an official Department of the Army position unless so designated by other authorized documents.
FOREWORD

In conducting the research described in this report, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources, National Research Council (DHEW Publication No. (NIH) 78-23, Revised 1978).
SUMMARY

Initial clinical studies of Phase I Q fever vaccine (IND #610) and skin test were performed under this contract. A total of 242 volunteers received skin tests and 22 received vaccine at two dose levels. Skin test reactions were classified according to the duration of persistence of erythema and skin test results were correlated with serologic and in vitro lymphocyte stimulation results. A role for lymphocyte testing in predicting skin test reactions was defined. In response to vaccine, local reactions were minimal and without abscess or granuloma formation. Immunologic results show consistent antibody responses and variable lymphocyte transformation responses to Q fever antigens.

Dermal granulomatous skin reactions seen to Q fever vaccine antigens in immune guinea pigs have been analyzed for their immunologic basis. New information has been obtained on the interrelations between antigens of C. burnetii and their relative contributions to granuloma formation. A purified fraction of C. burnetii obtained by extraction with chloroform and methanol (CMR) has been characterized as a skin and lymphocyte antigen in man and guinea pigs. CMR is devoid of granuloma reactivity but carries the determinant for delayed hypersensitivity and lymphocyte stimulation.

A solid phase (FIAx) immunofluorescent assay procedures was developed for serodiagnosis of Q fever and used in the evaluation of volunteers responses to Q fever vaccine and skin test as well as in an intensive national surveillance program.
1. **Clinical Studies of Q Fever Vaccine**

In this contract we conducted the initial studies of the IND 610 Q fever vaccine and skin test in man. 242 individuals received skin tests and 22 received vaccine. No serious adverse reactions have been noted in these subjects. Local reactions have been limited to transient erythema and pain without evidence of abscess or granuloma formation. Immunologic results show the appearance of antibody measured by FIAx immunofluorescence in all vaccinated subjects. These results are published. (Ascher, M.S., Berman, M.A., Ruppanner, R. Initial Clinical and Immunological Evaluation in Man of a New Phase I Q Fever Vaccine and Skin Test. J Inf Dis 148:214-222, 1983.)

Since our publication, the relationships between skin test results and serologic results have been analyzed in a larger group of individuals now comprising a total of 242 subjects. In the series of skin tested individuals, we have correlated skin test erythema diameter at 24 hours and the level of antibody measured by FIAx immunofluorescence. As presented in Table 1 and Figure 1, the relationship previously described still holds with the addition that some reactions read as only 4 mm at 24 hours are seen in individuals carrying antibody suggesting that these reactions must be considered significant. The overall correlation remains the same in this larger sample (r = .351, p = 0.001).

**TABLE 1**

CROSSTABULATION OF ANTIBODY LEVELS AND SKIN TEST DIAMETER

<table>
<thead>
<tr>
<th>MM at 24 hrs.</th>
<th>FIAx Immunofluorescence</th>
<th>Negative 0 to 37</th>
<th>Positive 38+</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 to 3</td>
<td>37</td>
<td>3</td>
<td>40</td>
<td></td>
</tr>
<tr>
<td></td>
<td>92.5</td>
<td>7.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4 to 9</td>
<td>16</td>
<td>14</td>
<td>30</td>
<td></td>
</tr>
<tr>
<td></td>
<td>53.3</td>
<td>46.7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10 to 19</td>
<td>48</td>
<td>33</td>
<td>81</td>
<td></td>
</tr>
<tr>
<td></td>
<td>59.3</td>
<td>40.7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20+</td>
<td>17</td>
<td>24</td>
<td>41</td>
<td></td>
</tr>
<tr>
<td></td>
<td>41.5</td>
<td>58.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>118</td>
<td>74</td>
<td>192</td>
<td></td>
</tr>
<tr>
<td></td>
<td>61.5</td>
<td>38.5</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
CORRELATION BETWEEN SKIN TEST AND ANTIBODY LEVEL

Figure 1

Correlation between fluorescence (FSU) and diameter of erythema (mm)

$r = 0.352$
$p < 0.001$
The next relationship we have been able to address is based on our observation that skin test types in individuals vary. We have classified skin reactions into 6 types based on the kinetics and intensity of development of erythema and induration. The types of reactions are classified as follows:

A) negative throughout 7 days of observation.
B) less than 4 mm at 25 hours becoming larger at 48.
C) greater than 10 mm at 24 hours becoming negative at 48 hours.
D) greater than 10 mm at 24 hours becoming smaller but not negative at 48 hours.
E) greater than 10 mm at 24 hours remaining the same at 48 hours.
F) positive at 24 hours becoming larger at 48 hours.

Based on this classification scheme we have tested the hypothesis that the type of skin reaction may correlate with the presence of antibody or its change after skin testing. One theoretical consideration is that circulation antibody might have a greater frequency on the Jones-Mote or type C reactions consistent with a suppressive effect of the humoral immune system on cellular immune functions. In contrast to this prediction, we find a direct correlation between the intensity of skin reactions and the frequency of antibody. The evanescent reactions (type C) had an antibody frequency of only 28% whereas the "solid" type F reactions had a frequency of 65%. The full breakdown of these data is presented in Table 2 and the quantitative relationship between these data is presented in Figure 2.

**TABLE 2**

**DISTRIBUTION OF ANTIBODY RESULTS BY SKIN TEST TYPE**

<table>
<thead>
<tr>
<th>FIAX Immunofluorescence</th>
<th>Negative 0-37u</th>
<th>Positive 38+u</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Skin test type</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A - Neg</td>
<td>37</td>
<td>2</td>
<td>39</td>
</tr>
<tr>
<td>C - Pos then 0</td>
<td>38</td>
<td>15</td>
<td>53</td>
</tr>
<tr>
<td>D - Pos then less</td>
<td>13</td>
<td>13</td>
<td>26</td>
</tr>
<tr>
<td>E - Pos then same</td>
<td>10</td>
<td>10</td>
<td>20</td>
</tr>
<tr>
<td>F - Pos then more</td>
<td>15</td>
<td>28</td>
<td>43</td>
</tr>
<tr>
<td>Column</td>
<td>113</td>
<td>68</td>
<td>181</td>
</tr>
</tbody>
</table>
Figure 2

FIAX ANTIBODY LEVELS
VERSUS SKIN TEST TYPE

Fluorescence (FSU)
Both the frequency of positive antibody (Table 2) and its level (Figure 2, one-way analysis of variance, p<0.05) are increased in higher grade reactions. The overall frequency of positive antibody in skin test positives is still only 47%.

Although antibody was not a very good predictor of skin reactivity, the possibility existed that the booster effects on antibody due to skin testing might be related to skin test type or intensity. In 60 individuals who were seronegative prior to skin test, we were able to obtain sera after skin test alone and have analyzed the change in antibody in FIAX units with respect to the intensity and type of skin reaction. In contrast to the results obtained with antibody prior to skin tests, there was no significant relationship between change in antibody and skin test type.

Finally, we have had the opportunity to analyze the antibody levels measured against the major virulence component of the organism, the phase I antigen. Phase I antibodies rarely persist after normal convalescence. There was a good correlation between the phase I antibody and the phase II antibody (data not shown) but there was no additional predictive relationship between the phase I antibody and skin test size type which was not already reflected in correlations with the phase II antibody.

**Skin testing**

One observation in the early trial was the low degree of skin test conversion obtained after vaccine. Although positive skin test reactions were seen in the individuals who experienced adverse local vaccine reactions, the skin test results were low grade and frequently not of a quality typical of delayed hypersensitivity. Further studies should be aimed at the effects of booster immunizations or skin test reactions and lymphocyte stimulation.

In addition, we have demonstrated a rise in antibody after skin testing alone in all individuals, regardless of skin test type as discussed above. These findings speak highly for the immunogenic potential of this vaccine since a dose as small as 20 ng boosts antibody in immunes. Previous studies have demonstrated antibody rises after a higher dose of vaccine given to skin test positive humans who developed rather severe local skin reactions. These recent findings validate the activity of the skin test reagent and strengthen the case for its continued use in clinical trials versus screening potential vaccines by serologic means.

**Lymphocyte testing**

More important prospects for a solution to the difficulty with serologic screening, however, come from our recent observations with the lymphocyte transformation test in these individuals. We have addressed in detail the relationships between various humoral and cellular immune tests and skin...
reactivity in the group of 74 skin tested individuals. There was a good overall correlation between FIAx antibody status and skin reactivity, but 22 out of 59 individuals who were antibody negative and positive skin tests in our test group. We have analyzed the correlations between serologic, skin test and lymphocyte data in the 27 individuals on whom complete studies were performed. Strong positive correlations were found between FIAx antibody status, skin reactivity and LT to both specific Phase I and Phase II antigens. LT results with the nonspecific mitogen PHA failed to correlate with any of these variables. Because all variables were highly intercorrelated, we then performed partial correlation analysis to assess the independence of these effects. Significant independent correlations were found between FIAx antibody and QII LT, between FIAx antibody and skin reactivity, and between skin reactivity and QI LT. Finally discriminant analysis was applied to determine the ability of the immunologic tests to predict skin reactivity. The best predictor was found to be FIAx antibody status, but a significant additional contribution was made by QI LT. No other factors added to the accuracy of classification. Overall, all 17 skin test negative individuals and 7 of 10 skin test positive individuals were correctly classified by the discriminant function using FIAx antibody and phase I LT results even though 5 of the latter group were antibody negative. Both FIAx antibody and QII-LT testing have a high proportion of false-negatives and false positives respectively and Phase I-LT is the best overall predictor of skin reactivity when analyzed in this way.

2. Studies of Dermal Granulomatous Hypersensitivity in Q Fever Immune Guinea Pigs

Studies on the granulomatous skin reactions seen to Q fever antigens in immune guinea pigs have concentrated on testing a variety of antigenic preparations of C. burnetii for their relative ability to induce or elicit such reactions. The findings of the studies are published. (Ascher, M.S., Berman, M.A., Parker, D., Turk, J.L. Experimental Model for Dermal Granulomatous Hypersensitivity in Q Fever. Inf Imm 39:388-393, 1983.) (Ascher, M.S., Williams, J.C., Berman, M.A. Dermal Granulomatous Hypersensitivity in Q Fever: Comparative Studies of the Granulomatous Potential of Whole Cells of Coxiella burnetii, Phase I and Subfractions. Inf Imm 42:887-889, 1983.) (Ascher, M.S., Williams, J.C., Berman, M.A. Cellular Immunologic Analysis of Coxiella burnetii Antigens. Microbiology 84.) In summary, the skin reactions were all qualitatively similar when either Phase I vaccines, Phase II vaccines, or TCA soluble and insoluble extracts were used to skin test Phase I immune animals. When animals were immunized with the various preparations and skin tested with whole cell Phase I vaccine, it was the group of Phase II immune animals which showed accelerated granuloma formation at three weeks. Parallel lymphocyte transformations studies revealed a high degree of cross reactivity between Phase I vaccine and TCA residue with a very selective response of Phase II immune animals to Phase II vaccine. These findings together suggest that the metabolic alteration which results in phase variation to Phase II produces
preferential expression of a specific "Phase II antigen" which is a significant contributor to the granulomatous reaction. One fraction, the residue of extraction by chloroform and methanol (CMR) elicits delayed hypersensitivity in sensitized guinea pigs with little or no granulomatous activity compared to whole cell products. These studies have also shown that the antigenic determinant responsible for induction and stimulation of lymphocyte reactivity in vitro is heavily represented in the CMR fraction. These findings lead to the proposal for initial testing of CMR vaccine in man.

3. FIAx Immunofluorescence Testing for Q Fever

In the two years of the contract our laboratory performed biosurveillance testing on over 1000 samples from 23 institutions inside and outside of California using our published FIAx technique (Ascher, M.S., Horwith, G.S., Thornton, M.F., Greenwood, J.R., Berman, M.A. A Rapid Immunofluorescent Procedure for Serodiagnosis of Q Fever in Mice, Guinea Pigs, Sheep and Humans. Diagnostic Immunology 1:33-38, 1983). Positive samples clearly illustrate the sensitivity of FIAx testing and its reliability for screening serum samples. Although there is little increase in fluorescence over the 16-128 CF range, there is little increase in fluorescence between CF titers of 8 and 16, the critical point of discrimination between "positive" and "negative" samples. Parallel testing of 40 of our samples by the unit at USAMRIID revealed agreement between their micro IF test and our FIAx results in 38 of 40 specimens.

As a result of recent laboratory outbreaks, two features of Q fever are bound to receive more attention in the future, the chronic disease state and endocarditis. The hallmark of these states is the presence of high titer specific antibody to phase I C. burnetii antigen. Given the fact that we have over 100 random positive sera on hand, we elected to survey a group of them for the presence of phase I antibody by FIAx. The thought was that a high phase I FIAx value may provide an early predictor of those at risk for chronic manifestations of Q fever. The results of this testing revealed a straightforward correlation between the two tests with no evidence of high phase I titers in this pilot group. The highest Phase I FIAx value was in a vaccinee. Two other samples with high positive phase II FIAx from suspect chronic cases were negative for phase I antibody. Since the publication of the manuscript, we have used the FIAx assay to characterize the class of immunoglobulin produced in response to infection or immunization. When two sequential sets of sera were compared, one from a clinical case and one from a vaccinee, equivalent FIAx values were obtained using a conjugated antiserum reactive against total immunoglobulin. When the IgG and IgM antibody classes were assayed separately the response of the clinical case was almost entirely IgG and the vaccinee's response IgM confirming previous results.

One additional observation with the FIAx assay in evaluating vaccine recipients has been that the fluctuations seen in antibody
levels after vaccine were greater than might be expected from this stable assay. Testing of immunoglobulin class of antibody retrospectively revealed sharp peaks of the IgM antibody associated with repeated skin tests. This finding may be useful in the follow-up of vaccinated individuals for evidence of subsequent infection.

We have also applied the FIA X assay to sera obtained from four different clinical situations 1) recent mild disease 2) vaccination 3) granulomatous hepatitis and 4) endocarditis. The titration of the quantitative FA result shows an extremely high titer of antibody in the chronic disease. We would therefore include a higher dilution in the evaluation of maximally reactive sera to screen for chronic disease. This result has direct utility in the clinical laboratory setting where FIA X technology is available and lessens the requirement for tedious dilution required in the standard microscopically read FA test.

4. Q Fever and Public Health

In addition to the recognized risk to military personnel of Q fever in natural exposure settings or biologic warfare, a number of institutional outbreaks have occurred associated with contact of humans with infected experimental sheep. The risk of this situation was first highlighted by an outbreak in 1979 at the University of California, San Francisco involving 150 cases and one death.

In 1980, year the UCSF outbreak, similar epidemics were noted at the University of Colorado Medical Center and at the Letterman Army Institute of Research in San Francisco (Ascher, unpublished). The next year, 1981, saw an outbreak reported from Bristol, England and in 1982 an identical situation occurred at the Hospital for Sick Children in Toronto, Canada. As was pointed out by Meikeljohn, these outbreaks were not always obvious, but in each case some individuals became severely ill, alerting physicians to look for the cause of the problem. The number of institutions with grants for conduct of sheep research was estimated by NIH to be 274 in 1981 with a total budget of $29 million. Every one of these units has the potential for Q fever transmission. The topic of laboratory acquired Q fever has been on the program of the American Association of Laboratory Animal Science national meeting and was a major symposium topic at the International Congress of Laboratory Animal Science in Vancouver in August of 1983. This symposium resulted in the formulation of an updated information statement (Grant, C.G., Ascher, M.S., Bernard, K.W., Ruppanner, R., Vellend, H. Q Fever and Experimental Sheep. Infection Control 6:122-123, 1985.)